News
Zacks Investment Research on MSN3d
KYMR Collaborates With GILD; Stock Down on Sanofi Deal UpdateKymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...
Zacks Investment Research on MSN3d
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan TagSanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...
Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.
GlobalData on MSN4d
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoidThe US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...
Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...
Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback